A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Foundation report highlighted in monthly brie...
Media - published on 01 Jul 2020

Foundation report highlighted in monthly briefing by FT Health

In this "monthly guide to big issues at the intersection of global health and finance," authors Andrew Jack and Darren Dodd collect a summary of relevant issues and news for FT Health.

This month's issue of FT Health focuses on the COVID-19 pandemic and its ever-changing associated health and financial issues. The Access to Medicine Foundation's latest publications on the "Big 3" burdens of HIV, malaria and TB is highlighted, along with a report from the Global Fund, in addressing the need to invest in these three epidemics in the wake of COVID-19 — and create child-friendly medicines in order to sustain previous progress made.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |